Our mission is to establish the first transcatheter ASD occluder with a metal-free frame as the new standard of care for atrial septal defects (ASDs).
Based in Switzerland and in the U.S., we have assembled an exceptional team with decades of experience at medical device start-ups and major corporations.
We have initiated our ASCENT-ASD pivotal trial in the United States and internationally to demonstrate the safety and efficacy of our reSept ASD Occluder for treating patients with clinically significant, isolated ASD. Our reSept ASD Occluder has received Investigational Device Exemption approval from the U.S. FDA.
Our company was founded by the Olle Larsson Holding AG (OLH), a Swiss corporate group with a diverse portfolio of companies in medical devices, among other sectors. Our ASD occluder was initially developed by Carag, a Swiss engineering and consulting firm, also an OLH company.